Valbenazine is a medicine used to treat uncontrolled body movements, like those in tardive dyskinesia and Huntington's disease. It's taken as a capsule once a day, and the Ingrezza Sprinkle capsule can be opened and sprinkled on soft food. It works by lowering the amount of dopamine, a brain chemical that helps control movement.
Every report comes from a Lived member, sent anonymously.
Have you tried Ingrezza (Valbenazine) for Tardive Dyskinesia?
Valbenazine, sold as Ingrezza, is a prescription medicine that reduces two kinds of involuntary movement in adults. The first is tardive dyskinesia, uncontrolled movements of the face, tongue or other parts of the body that can develop after long-term use of antipsychotic medicines or other drugs that block dopamine. The movements can be persistent and, for some people, disabling or embarrassing. The second is chorea in Huntington's disease, the sudden, irregular movements caused by this inherited condition, in which nerve cells in parts of the brain gradually break down. Valbenazine treats the movements themselves. It does not treat the mental health condition that the original medicine was prescribed for, and it does not slow Huntington's disease. Ingrezza comes as a regular capsule and as Ingrezza Sprinkle, a capsule that can be opened onto soft food; both contain the same medicine and are approved for the same uses. Valbenazine belongs to a group called VMAT2 (vesicular monoamine transporter 2) inhibitors. Deutetrabenazine (Austedo) is the other medicine in this group approved for both conditions.
Dopamine is a chemical messenger that, among many jobs, helps the brain fine-tune movement. Before nerve cells release dopamine, they pack it into tiny storage sacs using the VMAT2 carrier protein. Valbenazine temporarily blocks this carrier, so less dopamine is packed and released. Too much dopamine signaling in movement circuits is thought to drive the extra movements in tardive dyskinesia and Huntington's chorea, so turning it down can quiet them. The exact reason valbenazine helps is not fully understood. Because its effect is reversible, the movements generally return when the medicine is stopped.
Valbenazine is taken by mouth once a day, with or without food. Treatment usually starts at a lower dose and is increased: for tardive dyskinesia the dose is typically raised after one week, and for Huntington's chorea it is raised in steps every two weeks. Some people stay on a lower dose if that works well or the higher dose causes side effects. A lower dose is also usual for people with moderate or severe liver disease, people whose bodies break the drug down slowly for genetic reasons, and people taking certain interacting medicines. The regular capsule is swallowed whole. Ingrezza Sprinkle can be swallowed whole with water, or opened and the full contents stirred into about a tablespoon of soft food such as applesauce, yogurt or pudding, then eaten right away and followed by a glass of water. Do not mix it into milk or water, and do not crush or chew it. The sprinkle form should not be given through a feeding tube because it can block the tube.
Sleepiness and tiredness are the most common side effects. Until you know how valbenazine affects you, avoid driving or operating machinery. People with Huntington's disease in the main study also more often had hives, rash and trouble sleeping. Other effects include dry mouth, constipation, dizziness or unsteadiness, restlessness, and nausea or vomiting. Valbenazine can cause Parkinson-like symptoms, such as stiffness, slowed movement, tremor, unsteady walking or falls, and drooling. Serious cases have mostly appeared within the first two weeks after starting or raising the dose. Tell the prescriber if these develop, since a lower dose or stopping may be needed. In Huntington's disease these signs can be hard to tell apart from the disease itself. Swelling of the face, lips, eyelids, tongue or throat, or trouble breathing, can mean a dangerous allergic reaction: stop the medicine and get emergency care. Rarely, medicines that lower dopamine cause neuroleptic malignant syndrome, a reaction with high fever, stiff muscles, confusion, and a fast or irregular heartbeat or heavy sweating; this also needs emergency care.
In people with Huntington's disease, valbenazine can increase the risk of depression and suicidal thoughts or behavior, which are already more common with the disease. This is a boxed warning from the US Food and Drug Administration (FDA), the agency's most prominent kind. The prescriber weighs this risk against how much the chorea interferes with life, with extra caution for anyone with past depression or suicidal thoughts. People taking it, and their families, should report new or worsening low mood or unusual behavior changes to the prescriber promptly, and suicidal thoughts right away, the same day. Valbenazine can lengthen the QT interval, a measure of the heart's electrical recharge time on an ECG (electrocardiogram); a long QT can lead to dangerous heart rhythms. The effect is small at usual doses, but it can matter at higher blood levels, and the drug should be avoided by people born with long QT syndrome or with related rhythm problems. Contact the prescriber right away about fainting or a racing, pounding heartbeat. Several medicines change how valbenazine works. It should not be combined with MAOIs (monoamine oxidase inhibitors, an older class of antidepressants also used in Parkinson's disease), or started within 14 days of stopping one. Some antifungals and antibiotics, such as ketoconazole and clarithromycin, and some antidepressants, such as fluoxetine, paroxetine and bupropion, raise valbenazine levels and call for a lower dose. Other medicines speed up the liver's breakdown of valbenazine so much that it may not work, and are not recommended together. Examples are rifampin (an antibiotic used mainly for tuberculosis), carbamazepine (Tegretol, a seizure and mood-stabilizing medicine) and the supplement St. John's wort. Valbenazine also raises levels of digoxin, a heart medicine, which then needs checking. Tell every prescriber and pharmacist that you take it before starting anything new. Pregnancy data are limited, and animal studies showed harm to offspring, so discuss pregnancy plans with the prescriber. Avoid breastfeeding during treatment and for 5 days after the last dose.
Valbenazine reduces involuntary movements rather than eliminating them, and responses vary. In the main tardive dyskinesia trial, about 4 in 10 people on the highest dose had their movement score cut by at least half after six weeks, compared with fewer than 1 in 10 on placebo. In the Huntington's trial, chorea scores on a 28-point scale started near 12 and improved by about 4.6 points over 12 weeks, compared with 1.4 points on placebo. The benefit lasts only while the medicine is taken. In studies, movements returned toward their starting level after valbenazine was stopped, which is why most people with tardive dyskinesia need ongoing treatment. Follow-up visits check how the movements are responding, mood (especially in Huntington's disease), sleepiness, and any Parkinson-like symptoms. An ECG may be done before raising the dose in someone at higher risk of heart rhythm problems.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Ingrezza (Valbenazine), what you've noticed, or ask the community a question.